Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953000 | 0.90 | ALDH1A1 (0.47) | RAB9ABCL6KMT2AAPAF1HK1 | |
| SCHEMBL7944001 | 0.89 | HDAC8 (0.41) | RAB9AKMT2AL3MBTL1MEN1CYP3A4 | |
| SCHEMBL7952499 | 0.89 | NPC1 (0.43) | RAB9AKMT2AAPAF1HK1HKDC1 | |
| SCHEMBL7951970 | 0.87 | HTT (0.41) | KMT2AL3MBTL1MEN1CYP1A2CYP3A4 | |
| SCHEMBL7951197 | 0.86 | MEN1 (0.49) | KMT2APOLBL3MBTL1LTA4HMEN1 | |
| SCHEMBL7950867 | 0.83 | ALDH1A1 (0.48) | KMT2APOLBL3MBTL1LTA4HMEN1 | |
| SCHEMBL7951092 | 0.83 | ALDH1A1 (0.48) | KMT2APOLBL3MBTL1LTA4HMEN1 | |
| SCHEMBL7954609 | 0.82 | KMT2A (0.43) | RAB9ABCL6KMT2AAPAF1HK1 | |
| SCHEMBL7956585 | 0.79 | TAAR1 (0.48) | RAB9AKMT2AL3MBTL1MEN1CYP1A2 | |
| SCHEMBL7956773 | 0.78 | KMT2A (0.44) | RAB9AKMT2APOLBMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-30 | — | — | US | disclosed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | RAB9A 3923/4885BCL6 547/4885KMT2A 2918/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | RAB9A 3923/4885BCL6 547/4885KMT2A 2918/4885 |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | RAB9A 3923/4885BCL6 547/4885KMT2A 2918/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | RAB9A 3570/4885BCL6 749/4885KMT2A 3071/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | RAB9A 3923/4885BCL6 547/4885KMT2A 2918/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | RAB9A 3923/4885BCL6 547/4885KMT2A 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.